Located in Shijiazhuang, the manufacturing plant will be equipped with 48,000L bioreactor capacity
Project render: WuXi Biologics plans to have more than 220,000L manufacturing capacity by 2021
WuXi Biologics has announced that construction work has commenced on a Biologics Manufacturing Centre of excellence (MFG8). The project is being built in the city of Shijiazhuang, one hour train from Beijing.
The new Biologics Centre with 48,000L bioreactor capacity, one of the largest global facilities using disposable bioreactors, will be built to meet cGMP standards of the United States, the European Union and China.
It will be the 8th drug substance manufacturing facility of WuXi Biologics, which plans to have more than 220,000L manufacturing capacity by 2021.
“We are pleased to break ground today and look forward to the operations of this new Biologics Centre. This facility will enable WuXi Biologics to develop and manufacture biologics more cost effectively as well as to provide a robust supply chain network for our global partners and ultimately to benefit patients worldwide,” said Dr Chris Chen, Chief Executive Officer of WuXi Biologics.
A global open-access biologics technology company, WuXi Bio offers end-to-end solutions for biologics discovery, development and manufacturing.